Drs. Ruperto, Lovell, Woo, Prieur, Petty, Martini, and Giannini have received honoraria and/or consulting fees (less than $10,000) from Centocor for serving as members of the study steering committee. Dr. Lovell has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Hoffmann-LaRoche, Amgen, Novartis, Bristol-Myers Squibb, Abbott, and Xoma and (more than $10,000) from Regeneron. Dr. Saurenmann has received honoraria (less than $10,000) from Essex for serving as a member of the Remicade “Switzerland” advisory board. Drs. Travers, Beutler, Keenan, Clark, Visvanathan, Fasanmade, Raychaudhuri, and Mendelsohn own stock or stock options in Johnson & Johnson, of which Centocor, Inc., is a subsidiary.
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis†
Article first published online: 30 AUG 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 56, Issue 9, pages 3096–3106, September 2007
How to Cite
Ruperto, N., Lovell, D. J., Cuttica, R., Wilkinson, N., Woo, P., Espada, G., Wouters, C., Silverman, E. D., Balogh, Z., Henrickson, M., Apaz, M.-T., Baildam, E., Fasth, A., Gerloni, V., Lahdenne, P., Prieur, A.-M., Ravelli, A., Saurenmann, R. K., Gamir, M. L., Wulffraat, N., Marodi, L., Petty, R. E., Joos, R., Zulian, F., McCurdy, D., Myones, B. L., Nagy, K., Reuman, P., Szer, I., Travers, S., Beutler, A., Keenan, G., Clark, J., Visvanathan, S., Fasanmade, A., Raychaudhuri, A., Mendelsohn, A., Martini, A. and Giannini, E. H. (2007), A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis & Rheumatism, 56: 3096–3106. doi: 10.1002/art.22838
ClinicalTrials.gov identifier: NCT00036374.
- Issue published online: 30 AUG 2007
- Article first published online: 30 AUG 2007
- Manuscript Accepted: 16 MAY 2007
- Manuscript Received: 25 OCT 2006
- Centocor, Inc.
- 6Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191–201., , , , , , et al, for the
- 10Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218–26., , , , , , et al, for the
- 15Efficacy of repeated intravenous infusions of an anti–tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52: 548–53., , , , , , et al.
- 17American Thoracic Society/CDC Statement Committee on Latent Tuberculosis Infection. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49: 1–51.
- 24A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum 2005; 52: 563–72., , , , , , et al.
- 25Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol 2006; 33: 985–95., , , , , , et al.
- 2648-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA) [abstract]. Ann Rheum Dis 2006; 65 Suppl II: 56., , , , , , et al.
- 27Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA) [abstract]. Ann Rheum Dis 2006; 65 Suppl II: 248., , , , , , et al.
- 28A meta-analysis to estimate the “real” placebo effect in juvenile rheumatoid arthritis (JRA) trials [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S90., , , , , .
- 29Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43., , , , , , et al, for the